帕利泊芬血管靶向光动力疗法对比主动监测治疗低危前列腺癌(CLIN1001 PCM301):一项开放标签、3期、随机对照试验
24个月时,光动力疗法组疾病进展比例低于主动监测组(28% vs 58%;校正HR 0.34,95%CI 0.24-0.46;p<0.0001),且活检阴性率更高(49% vs 14%;校正RR 3.67,95%CI 2.53-5.33;p<0.0001)。作者认为该疗法安全有效,可能使更多男性考虑保留组织的方法并推迟或避免根治性治疗。
要点
- 24个月疾病进展:光动力疗法组28% vs 主动监测组58%,校正HR 0.34(95%CI 0.24-0.46;p<0.0001)。
- 24个月活检阴性:光动力疗法组49% vs 主动监测组14%,校正RR 3.67(95%CI 2.53-5.33;p<0.0001)。
- 光动力疗法耐受良好;常见3-4级不良事件为前列腺炎、急性尿潴留和勃起功能障碍。
核心结论
- 帕利泊芬血管靶向光动力疗法是低危局限性前列腺癌安全、有效的治疗,可能使更多男性考虑保留组织的方法并推迟或避免根治性治疗。
研究设计与样本
- 开放标签、3期随机对照试验,在47个欧洲大学中心和社区医院开展。
- 纳入未接受过治疗的低危局限性前列腺癌(Gleason 3型)男性,按1:1随机分配至血管靶向光动力疗法组(206例)或主动监测组(207例)。
- 光动力疗法方案:帕利泊芬4 mg/kg静脉输注10分钟,光纤插入前列腺覆盖目标治疗区,随后以753 nm激光、固定功率150 mW/cm激活22分15秒。
- 主动监测遵循设计时的最佳实践:每12个月活检,每3个月检测前列腺特异性抗原和直肠指检。
- 主要终点为治疗失败(24个月随访期间组织学进展为中度或高危或死亡)和确切无癌(第24个月无任何组织学结果确切阳性)。
主要发现
- 中位随访24个月(IQR 24-25)。
- 第24个月疾病进展比例:光动力疗法组58/206(28%)vs 主动监测组120/207(58%),校正HR 0.34(95%CI 0.24-0.46;p<0.0001)。
- 治疗后24个月前列腺活检阴性:光动力疗法组101/206(49%)vs 主动监测组28/207(14%),校正RR 3.67(95%CI 2.53-5.33;p<0.0001)。
- 最常见3-4级不良事件:前列腺炎光动力疗法组3例(2%)vs 主动监测组1例(<1%);急性尿潴留3例(2%)vs 1例(<1%);勃起功能障碍2例(1%)vs 3例(1%)。
- 光动力疗法组最常见严重不良事件为尿潴留(15例;其中3例严重),所有患者2个月内缓解;主动监测组最常见严重不良事件为心肌梗死(3例)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial. METHODS: This randomised controlled trial was done in 47 European university centres and community hospitals. Men with low-risk, localised prostate cancer (Gleason pattern 3) who had received no previous treatment were randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min and optical fibres inserted into the prostate to cover the desired treatment zone and subsequent activation by laser light 753 nm with a fixed power of 150 mW/cm for 22 min 15 s) or active surveillance. Randomisation was done by a web-based allocation system stratified by centre with balanced blocks of two or four patients. Best practice for active surveillance at the time of study design was followed (ie, biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal examination at 3-month intervals). The co-primary endpoints were treatment failure (histological progression of cancer from low to moderate or high risk or death during 24 months' follow-up) and absence of definite cancer (absence of any histology result definitely positive for cancer at month 24). Analysis was by intention to treat. Treatment was open-label, but investigators assessing primary efficacy outcomes were masked to treatment allocation. This trial is registered with ClinicalTrials.gov, number NCT01310894. FINDINGS: Between March 8, 2011, and April 30, 2013, we randomly assigned 206 patients to vascular-targeted photodynamic therapy and 207 patients to active surveillance. Median follow-up was 24 months (IQR 24-25). The proportion of participants who had disease progression at month 24 was 58 (28%) of 206 in the vascular-targeted photodynamic therapy group compared with 120 (58%) of 207 in the active surveillance group (adjusted hazard ratio 0·34, 95% CI 0·24-0·46; p<0·0001). 101 (49%) men in the vascular-targeted photodynamic therapy group had a negative prostate biopsy result at 24 months post treatment compared with 28 (14%) men in the active surveillance group (adjusted risk ratio 3·67, 95% CI 2·53-5·33; p<0·0001). Vascular-targeted photodynamic therapy was well tolerated. The most common grade 3-4 adverse events were prostatitis (three [2%] in the vascular-targeted photodynamic therapy group vs one [<1%] in the active surveillance group), acute urinary retention (three [2%] vs one [<1%]) and erectile dysfunction (two [1%] vs three [1%]). The most common serious adverse event in the vascular-targeted photodynamic therapy group was retention of urine (15 patients; severe in three); this event resolved within 2 months in all patients. The most common serious adverse event in the active surveillance group was myocardial infarction (three patients). INTERPRETATION: Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for low-risk, localised prostate cancer. This treatment might allow more men to consider a tissue-preserving approach and defer or avoid radical therapy. FUNDING: Steba Biotech.
引用
- Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016. PMID: 28007457. doi:10.1016/S1470-2045(16)30661-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。